Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
BOSTON, March 01, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will release its fourth quarter and fiscal year 2015 financial results on Tuesday, March 15, 2016. In conjunction with the release, the Company has scheduled a conference call and webcast on Tuesday, March 15, 2016 at 8:00 a.m. ET to discuss the financial results and provide a business update.
Conference Call Information
When: Tuesday, March 15, 2016, 8:00 a.m. ET
Dial-in: 1-855-638-3957 (United States) or 1-224-633-1318 (International)
Conference ID: 58250825
Webcast: http://ir.epirusbiopharma.com/events.cfm
Please join the conference call at least 10 minutes early to register.
The webcast will be archived on EPIRUS' website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. The company’s current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®), currently marketed outside the U.S. and in an ongoing global Phase 3 study for registration in Europe and North America; BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)i. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets.
i. Remicade is a registered trademark of Johnson and Johnson; Humira is a registered trademark of AbbVie; Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group; Stelara is owned and marketed by Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson and Johnson; Simponi is marketed by Janssen Biotech Inc; Soliris is a registered trademark of Alexion Pharmaceuticals, Inc.
Contact Information For investor inquiries: Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected] For media inquiries: Hope Buggey, FleishmanHillard +1-919-336-3786 [email protected]
